支持:13376277882 | tech@naturebios.com

祝贺 徐州医科大学时晓庆老师和丁佳戈老师论文发表

日期:2023/02/20 类型:The Wall

祝贺:时晓庆老师和丁佳戈老师 

    恭喜您们在学术道路上又取得了新的成就!您们的文献发表是对多年来不懈追求学术进步的最好证明,更是您们所掌握知识的体现,祝愿您在未来的学术道路上继续勇往直前,创造更多辉煌的成就!
        

        时小庆感言:未来之路,需要不断努力,既然选择了医学,就要坚持自己的使命。


        丁佳戈感言:不管遇到什么困难,只要坚持去做,就会越来越好,离成功也就越来越近


        柴大飞导师寄语:自信,自立,自强,去追逐梦想,实现人生价值。

        HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma

        简介:Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited the subcutaneous tumor growth, while increasing the infiltration of CD8+T cells and DCs. Furthermore, the PLGA/PEI-HMGB1/GPC3 vaccine induced a strong CTL effect and promoted functional CD8+T cell proliferation. Intriguingly, the depletion assay proved that the therapeutic effect PLGA/PEI-HMGB1/GPC3 vaccine was dependent on antigen-specific CD8+T cell immune responses. In the rechallenge experiment, PLGA/PEI-HMGB1/GPC3 vaccine provided a long-lasting resistance to the growth of the contralateral tumor by inducing the memory CD8+T cell responses. Collectively, PLGA/PEI-HMGB1/GPC3 vaccine could induce a strong and long-lasting CTL effect and inhibit the tumor progression or re-attack. Therefore, the combined co-immunization of PLGA/PEI-HMGB1/GPC3 might be served as an effective anti-tumor strategy against HCC.


232c30b215c2ddcb5f37795f5396d87.pngf5524b3367f6d837235e5df84aef3b4e_.jpg